Suppr超能文献

泛素特异性蛋白酶5(Usp5)将黑色素瘤中p53和FAS水平的抑制与BRAF信号通路联系起来。

Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway.

作者信息

Potu Harish, Peterson Luke F, Pal Anupama, Verhaegen Monique, Cao Juxiang, Talpaz Moshe, Donato Nicholas J

机构信息

Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.

Department of Dermatology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.

出版信息

Oncotarget. 2014 Jul 30;5(14):5559-69. doi: 10.18632/oncotarget.2140.

Abstract

Usp5 is a deubiquitinase (DUB) previously shown to regulate unanchored poly-ubiquitin (Ub) chains, p53 transcriptional activity and double-strand DNA repair. In BRAF mutant melanoma cells, Usp5 activity was suppressed by BRAF inhibitor (vemurafenib) in sensitive but not in acquired or intrinsically resistant cells. Usp5 knockdown overcame acquired vemurafenib resistance and sensitized BRAF and NRAS mutant melanoma cells to apoptosis initiated by MEK inhibitor, cytokines or DNA-damaging agents. Knockdown and overexpression studies demonstrated that Usp5 regulates p53 (and p73) levels and alters cell growth and cell cycle distribution associated with p21 induction. Usp5 also regulates the intrinsic apoptotic pathway by modulating p53-dependent FAS expression. A small molecule DUB inhibitor (EOAI3402143) phenocopied the FAS induction and apoptotic sensitization of Usp5 knockdown and fully blocked melanoma tumor growth in mice. Overall, our results demonstrate that BRAF activates Usp5 to suppress cell cycle checkpoint control and apoptosis by blocking p53 and FAS induction; all of which can be restored by small molecule-mediated Usp5 inhibition. These results suggest that Usp5 inhibition can provide an alternate approach in recovery of diminished p53 (or p73) function in melanoma and can add to the targeted therapies already used in the treatment of melanoma.

摘要

Usp5是一种去泛素化酶(DUB),先前已证明它可调节未锚定的多聚泛素(Ub)链、p53转录活性和双链DNA修复。在BRAF突变的黑色素瘤细胞中,BRAF抑制剂(维莫非尼)可抑制敏感细胞中的Usp5活性,但对获得性耐药或固有耐药细胞无效。敲低Usp5可克服获得性维莫非尼耐药,并使BRAF和NRAS突变的黑色素瘤细胞对MEK抑制剂、细胞因子或DNA损伤剂引发的凋亡敏感。敲低和过表达研究表明,Usp5调节p53(和p73)水平,并改变与p21诱导相关的细胞生长和细胞周期分布。Usp5还通过调节p53依赖性FAS表达来调节内源性凋亡途径。一种小分子DUB抑制剂(EOAI3402143)模拟了Usp5敲低后的FAS诱导和凋亡致敏作用,并完全阻断了小鼠黑色素瘤肿瘤的生长。总体而言,我们的结果表明,BRAF通过阻断p53和FAS诱导来激活Usp5,从而抑制细胞周期检查点控制和凋亡;所有这些都可以通过小分子介导的Usp5抑制来恢复。这些结果表明,抑制Usp5可以为恢复黑色素瘤中p53(或p73)功能减弱提供另一种方法,并可补充已用于治疗黑色素瘤的靶向疗法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验